Tagged: Amicus Briefs

Gibbons Attorneys Draft NJSBA Amicus Brief Challenging Jury Selection in First In-Person Trial Since Pandemic

Lawrence S. Lustberg and Michael R. Noveck, Director and Fellow, respectively, of the John J. Gibbons Fellowship in Public Interest & Constitutional Law at Gibbons P.C., researched and drafted the amicus brief filed yesterday by the New Jersey State Bar Association (NJSBA), challenging the jury selection process in the first in-person trial to resume in New Jersey since the COVID-19 pandemic state of emergency was declared. Christine A. Amalfe, Chair of the Gibbons Employment & Labor Law Department and NJSBA Secretary and member of its Pandemic Task Force, arranged for the firm to handle the matter pro bono for the bar association. “As it has been doing for 30 years, the Gibbons Fellowship continues to tackle cutting-edge issues of justice and equality in our criminal courts,” said Patrick C. Dunican Jr., Chairman and Managing Director of the firm. “Fairness to the accused is paramount, even as courts face understandable difficulties as they try to return to normal operations while gradually emerging from the COVID crisis, which Larry and Mike argue very effectively in the NJSBA’s brief.” The matter at issue, State v. Dangcil, is a criminal trial in Bergen County that began last week. The NJSBA argued in the brief authored by Mr. Lustberg and Mr. Noveck that the jury management office exercised its own...

Gibbons Institute of Law, Science & Technology Files Amicus Brief in “Pay-for-Delay” Case Before Supreme Court

We previously reported on the battle over so-called “pay-for-delay” settlements, which puts the pharmaceutical industry versus the Federal Trade Commission (“FTC”) before the Supreme Court, to decide the legality of reverse payments in Hatch-Waxman cases. The case is FTC v. Actavis, Inc., et al. Last week, the Gibbons Institute of Law, Science & Technology, among 16 other amici, filed briefs in support of respondents and the lawfulness of these payments. The other amici included: Antitrust Economists; Bayer AG and Bayer Corp.; Health Economics and Law Professors; Mediation and Negotiation Professionals; Law Professors Gregory Dolin, Kent Bernard, et al.; The American Intellectual Property Law Association; Enavail, LLC; The Generic Pharmaceutical Association]; Intellectual Property Owners Association; Merck & Co., Inc.; National Association of Manufacturers; Pharmaceutical Research and Manufacturers of America (Phrma); New York Intellectual Property Law Association; Shire plc; Washington Legal Foundation; Generic Manufacturers Upsher-Smith Laboratories, Inc.; Teva Pharmaceuticals USA, Inc.; Ranbaxy Pharmaceuticals, Inc.; Mylan Pharmaceuticals Inc.; and Impax Laboratories, Inc.